Alx Oncology Holdings Inc (ALXO)

$1.38 +0.16 (13.11%)
Market Cap 66.15M
Revenue (ttm) 0.00
Net Income (ttm) -134.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.23
Volume 826,000
Avg Vol 559,216
Day's Range N/A - N/A
Shares Out 54.22M
Stochastic %K 60%
Beta 1.23
Analysts Strong Sell
Price Target $2.50

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 466 7125
Address:
323 Allerton Avenue, South San Francisco, United States
StarLord13
StarLord13 Nov. 14 at 9:01 PM
$ALXO Nice start to the weekend.
0 · Reply
GoImugene
GoImugene Nov. 14 at 5:16 PM
$ALXO high expectations for this Phase 2 clinical trial result to complete in March of next year. Phase 1 results were spectacular. https://clinicaltrials.gov/study/NCT05025800
0 · Reply
StarLord13
StarLord13 Nov. 14 at 4:33 PM
$ALXO Up 20% today on no news. My price avrg is right at this level. To sell and buy more on any drop or to hold 🤔
1 · Reply
Wizzard88
Wizzard88 Nov. 14 at 4:31 PM
$ALXO Do not tag other tickers here ! Keep it silent 🤫
0 · Reply
StarLord13
StarLord13 Nov. 14 at 2:44 PM
$ALXO only green on my watch list👀
1 · Reply
BillionerOfKing
BillionerOfKing Nov. 11 at 12:12 PM
$ALXO Current Stock Price: $1.27 Contracts to trade: $0.5 ALXO Nov 21 2025 Call Entry: $1.22 Exit: $2.43 ROI: 100% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
P119
P119 Nov. 7 at 9:45 PM
$ALXO 2+ by end of this month
0 · Reply
StarLord13
StarLord13 Nov. 7 at 8:42 PM
$ALXO 35% move so far off the lows of the day. What a bounce.
0 · Reply
P119
P119 Nov. 7 at 8:29 PM
$ALXO Monday could be a interesting day here
0 · Reply
StarLord13
StarLord13 Nov. 7 at 8:12 PM
$ALXO Lmao, what a crazy week. This market is wild!
0 · Reply
Latest News on ALXO
ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 3:56 PM EST - 7 days ago

ALX Oncology Holdings Inc. (ALXO) Q3 2025 Earnings Call Transcript

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 7, 2025, 8:15 AM EST - 7 days ago

ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

Oct 30, 2025, 8:30 AM EDT - 15 days ago

ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

Oct 23, 2025, 12:30 PM EDT - 22 days ago

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 3, 2025, 9:05 AM EDT - 6 weeks ago

ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

Sep 12, 2025, 8:30 AM EDT - 2 months ago

ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer

ALX Oncology to Participate in Upcoming Investor Conferences in September

Aug 29, 2025, 12:00 PM EDT - 2 months ago

ALX Oncology to Participate in Upcoming Investor Conferences in September

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

Aug 19, 2025, 8:00 AM EDT - 3 months ago

ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 9:45 PM EDT - 3 months ago

ALX Oncology Holdings Inc. (ALXO) Q2 2025 Earnings Call Transcript

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 4:05 PM EDT - 3 months ago

ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

Aug 5, 2025, 8:00 AM EDT - 3 months ago

ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

May 30, 2025, 8:00 AM EDT - 6 months ago

ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

May 20, 2025, 8:00 AM EDT - 6 months ago

ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

May 13, 2025, 8:00 AM EDT - 6 months ago

ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:30 AM EDT - 6 months ago

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

May 2, 2025, 8:00 AM EDT - 7 months ago

ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

Apr 25, 2025, 1:10 PM EDT - 7 months ago

ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

Apr 25, 2025, 9:00 AM EDT - 7 months ago

ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:01 PM EST - 9 months ago

ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Mar 5, 2025, 8:00 AM EST - 9 months ago

ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Feb 27, 2025, 8:00 AM EST - 9 months ago

ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

ALX Oncology to Host Virtual R&D Day on March 5, 2025

Feb 18, 2025, 8:00 AM EST - 9 months ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

Jan 23, 2025, 8:00 AM EST - 10 months ago

ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

Jan 22, 2025, 4:01 PM EST - 10 months ago

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

Jan 21, 2025, 5:00 PM EST - 10 months ago

ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

Dec 18, 2024, 8:00 AM EST - 11 months ago

ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

Nov 14, 2024, 8:00 AM EST - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 4:00 PM EST - 1 year ago

ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

Nov 1, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

Sep 11, 2024, 10:36 PM EDT - 1 year ago

ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

Aug 6, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

Jul 31, 2024, 4:01 PM EDT - 1 year ago

ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Jul 31, 2024, 5:30 AM EDT - 1 year ago

ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27, 2024, 4:13 AM EDT - 1 year ago

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

Jun 2, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

May 29, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:00 PM EDT - 1 year ago

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Appoints Allison Dillon as Chief Business Officer

May 7, 2024, 9:00 AM EDT - 1 year ago

ALX Oncology Appoints Allison Dillon as Chief Business Officer

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024, 10:00 AM EDT - 1 year ago

ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

Apr 9, 2024, 5:30 PM EDT - 1 year ago

ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 7, 2024, 4:03 PM EST - 1 year ago

ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 1 year ago

ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

ALX Oncology shares jump 9% after Jefferies upgrade

Dec 8, 2023, 8:30 AM EST - 2 years ago

ALX Oncology shares jump 9% after Jefferies upgrade

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 4:05 PM EST - 2 years ago

ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 10, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

Oct 9, 2023, 12:38 AM EDT - 2 years ago

ALX Oncology: On Right Track With Latest Interim Analysis Of Evorpacept

ALX Oncology Announces Pricing of Public Offering

Oct 5, 2023, 8:00 AM EDT - 2 years ago

ALX Oncology Announces Pricing of Public Offering

ALX Oncology Announces Proposed Public Offering

Oct 4, 2023, 4:10 PM EDT - 2 years ago

ALX Oncology Announces Proposed Public Offering

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 3, 2023, 6:00 AM EDT - 2 years ago

ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

Oct 2, 2023, 4:05 PM EDT - 2 years ago

ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer

StarLord13
StarLord13 Nov. 14 at 9:01 PM
$ALXO Nice start to the weekend.
0 · Reply
GoImugene
GoImugene Nov. 14 at 5:16 PM
$ALXO high expectations for this Phase 2 clinical trial result to complete in March of next year. Phase 1 results were spectacular. https://clinicaltrials.gov/study/NCT05025800
0 · Reply
StarLord13
StarLord13 Nov. 14 at 4:33 PM
$ALXO Up 20% today on no news. My price avrg is right at this level. To sell and buy more on any drop or to hold 🤔
1 · Reply
Wizzard88
Wizzard88 Nov. 14 at 4:31 PM
$ALXO Do not tag other tickers here ! Keep it silent 🤫
0 · Reply
StarLord13
StarLord13 Nov. 14 at 2:44 PM
$ALXO only green on my watch list👀
1 · Reply
BillionerOfKing
BillionerOfKing Nov. 11 at 12:12 PM
$ALXO Current Stock Price: $1.27 Contracts to trade: $0.5 ALXO Nov 21 2025 Call Entry: $1.22 Exit: $2.43 ROI: 100% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
P119
P119 Nov. 7 at 9:45 PM
$ALXO 2+ by end of this month
0 · Reply
StarLord13
StarLord13 Nov. 7 at 8:42 PM
$ALXO 35% move so far off the lows of the day. What a bounce.
0 · Reply
P119
P119 Nov. 7 at 8:29 PM
$ALXO Monday could be a interesting day here
0 · Reply
StarLord13
StarLord13 Nov. 7 at 8:12 PM
$ALXO Lmao, what a crazy week. This market is wild!
0 · Reply
Wizzard88
Wizzard88 Nov. 7 at 8:00 PM
$ALXO My only mistake was starting position 2 days ago and not today !
1 · Reply
MakingMoneyHere
MakingMoneyHere Nov. 7 at 7:50 PM
$ALXO 6 dolllats to February!
0 · Reply
StarLord13
StarLord13 Nov. 7 at 5:37 PM
$ALXO Now under the CEO’s most recent purchase. This >10% drop every single day is making this the worst performing bio on my watchlist. Was considering averaging down at a dollar, not so certain anymore.
0 · Reply
danial88
danial88 Nov. 7 at 5:00 PM
$ALXO This shame less shit dropped non stop since I bought 😢😢😢
0 · Reply
danial88
danial88 Nov. 7 at 4:58 PM
$ALXO Why I bought this piece of shit at 1.60 😭😭😭😭
0 · Reply
StarLord13
StarLord13 Nov. 7 at 2:32 PM
$ALXO Flat open after earnings even with favourable results. Think this tests $1 before any meaningful bounce with this kind of price action.
1 · Reply
MakingMoneyHere
MakingMoneyHere Nov. 7 at 1:21 PM
$ALXO Well good news
0 · Reply
StarLord13
StarLord13 Nov. 7 at 1:17 PM
$ALXO https://www.stocktitan.net/news/ALXO/alx-oncology-reports-third-quarter-2025-financial-results-and-1wlj8oykd0px.html
0 · Reply
Wizzard88
Wizzard88 Nov. 7 at 1:49 AM
$ALXO Why stocktwit shows %17 AH pop ?!!!
2 · Reply
S2K_TP
S2K_TP Nov. 7 at 12:38 AM
🚨 Major Friday's earnings releases before bell: $ALXO before bell $WEN before bell $CGC before bell $MOGO before bell $KKR before bell
0 · Reply
Wizzard88
Wizzard88 Nov. 6 at 8:54 PM
$ALXO What a roller coaster 🤣
0 · Reply
P119
P119 Nov. 6 at 8:52 PM
$ALXO first half followed by second 😆
0 · Reply